Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425462 | 1.00 | MAPK1 (0.34) | MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL6161938 | 1.00 | MAPK1 (0.34) | MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL6108339 | 0.83 | MAPK1 (0.33) | MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL6432031 | 0.83 | MAPK1 (0.33) | MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL14570178 | 0.80 | KMT2A (0.40) | — | |
| SCHEMBL9036688 | 0.80 | KMT2A (0.40) | — | |
| SCHEMBL9645913 | 0.76 | LMNA (0.36) | — | |
| SCHEMBL9645916 | 0.76 | LMNA (0.36) | — | |
| SCHEMBL950964 | 0.74 | HTT (0.35) | — | |
| SCHEMBL951739 | 0.74 | HTT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218237-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218237-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218235-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218235-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-1233017-B1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218237-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC26A4, SLC26A3, SLC10A1 | MAPK1 2823/4885CHRM2 919/4885CHRM1 659/4885 |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC26A4, SLC26A3, SLC10A1 | MAPK1 2823/4885CHRM2 919/4885CHRM1 659/4885 |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MAPK1 2107/4885CHRM2 4004/4885CHRM1 4356/4885 |
| US-20110218235-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC10A1, CYP7A1, SLC39A11 | MAPK1 4242/4885CHRM2 1872/4885CHRM1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.